/wp-content/uploads/2023/06/2020-ASHP-How-to-Design-MUE.pdf#new_tab/wp-content/uploads/2023/06/2023-MUE-MS-Biosimilars-template.docx#new_tab/wp-content/uploads/2023/06/2023-MUE-PowerPoint-Template.pptx#new_tab/wp-content/uploads/2023/06/ASHP-Guidelines-on-Medication-Use-Evaluation.pdf#new_tab/wp-content/uploads/2023/06/Biosimilar-Monograph-Template-1.docx#new_tab/wp-content/uploads/2023/06/Biosimilar-strategic-implementation-at-a-large-health-system-AJHP-2022.pdf#new_tab/wp-content/uploads/2023/06/biosimilars-in-the-us-reimbursement-and-impacts-to-uptake.pdf#new_tab/wp-content/uploads/2023/06/FormularyMonographServicesToolkitContent2018.docx#new_tab/wp-content/uploads/2023/06/GHLF_Biosimilars_Patient_Guidelines_2018.pdf#new_tab/wp-content/uploads/2023/06/Healthcare-system-conversion-to-a-biosimilar-AJHP-2021.pdf#new_tab/wp-content/uploads/2023/06/How-to-Select-a-best-value-biosogical-medicine-AJHP.pdf#new_tab/wp-content/uploads/2023/06/Implementation-Checklist-1.docx#new_tab/wp-content/uploads/2023/06/Monograph-Presentation-Checklist-3.docx#new_tab/wp-content/uploads/2023/06/New-Biosimilar-Product-Interactive-Checklist.pdf#new_tabhttps://biosimilarsrr.com/2022/07/26/sandoz-submits-351k-application-for-biosimilar-natalizumab-to-treat-ms/#new_tabhttps://www.novartis.com/news/media-releases/applications-proposed-first-kind-multiple-sclerosis-biosimilar-natalizumab-accepted-us-fda-and-ema#new_tabhttps://www.centerforbiosimilars.com/view/eye-on-pharma-natalizumab-injunction-oral-ustekinumab-development-and-new-study-for-secukinumab-biosimilar#new_tabhttps://www.managedhealthcareexecutive.com/view/biosimilar-to-tysabri-for-relapsing-remitting-ms-on-the-way#new_tabhttps://multiplesclerosisnewstoday.com/news-posts/2022/08/26/guidelines-approval-dmt-biosimilars-use-europe-drafted/#new_tabhttps://journals.sagepub.com/doi/full/10.1177/13524585221116269#new_tabhttps://n.neurology.org/content/98/18_Supplement/1103#new_tabhttps://multiplesclerosisnewstoday.com/news-posts/2023/02/03/biosimilar-pb006-comparable-safety-efficacy-tysabri-phase-3/#new_tabhttps://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/#new_tabhttps://www.centerforbiosimilars.com/biosimilar-approvals#new_tabhttps://ashpadvantagemedia.com/adoptbiosimilars/files/ASHP_Biosimilars_Report_FINAL.pdf#new_tabhttps://www.ashp.org/professional-development/ashp-podcasts/hot-topics-in-pharmacy-practice/managing-biosimilars-a-specialty-all-its-own?loginreturnUrl=SSOCheckOnly#new_tabhttps://www.ashp.org/professional-development/ashp-podcasts/ashp-advantage/best-practices-in-formulary-management-unique-strategies-for-biosimilar-adoption#new_tabhttps://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/state-regulations-for-biosimilar.html#new_tabhttps://pubmed.ncbi.nlm.nih.gov/30110587/#new_tabhttps://academic.oup.com/oncolo/article/23/11/1261/6439727#new_tabhttps://jnccn.org/view/journals/jnccn/9/Suppl_4/article-pS-1.xml?ArticleBodyColorStyles=inline%20pdf#new_tab/wp-content/uploads/2023/06/Factors-influencing-the-economics-of-bisimilars-in-the-US.pdf#new_tabhttps://academic.oup.com/ajhp/article/78/3/249/6026555?login=false#new_tabhttps://www.jmcp.org/doi/10.18553/jmcp.2021.27.8.1129#new_tabhttps://link.springer.com/article/10.1007/s40273-017-0529-x#new_tabhttps://www.eric.org/wp-content/uploads/2020/03/FINAL-ERICBiosimilarsAtTenYearsInfographic.pdf#new_tabhttps://www.tandfonline.com/doi/full/10.1080/14712598.2021.1849132#new_tabhttps://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars#new_tabhttps://pubmed.ncbi.nlm.nih.gov/35552095/#new_tabhttps://rmdopen.bmj.com/content/7/2/e001637#new_tabhttps://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-biosimilars-report-2023.pdf#new_tabhttps://pubmed.ncbi.nlm.nih.gov/30487998/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/23687260/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/33651341/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/28502609/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/29045077/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/33546755/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/29439591/#new_tabhttps://www.psoriasis.org/position-statement-on-biosimilars/#new_tabhttps://www.psoriasis.org/biosimilars/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/34273158/#new_tabhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11325#new_tabhttps://www.ahdbonline.com/issues/2022/june-2022-vol-15-no-2/3222-implementation-strategies-of-biosimilars-in-healthcare-systems-the-path-forward#new_tabhttps://ard.bmj.com/content/75/Suppl_2/879.3#new_tabhttps://www.jmcp.org/doi/full/10.18553/jmcp.2020.26.4.410?role=tab#new_tabhttps://link.springer.com/article/10.1007/s40259-021-00510-w#new_tabhttps://biosimilarsinneurology.com/#new_tabhttps://mscare.sharefile.com/share/view/s9f217488525840428fa35a051065d153#new_tabhttps://www.ajmc.com/view/biosimilarssuppl-currentevidence#new_tabhttps://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or#new_tabhttps://link.springer.com/article/10.1007/s40744-020-00259-8#new_tabhttps://cdn.sanity.io/files/0vv8moc6/ajmc/38827df77fa2d0754278e1c18fde6b4ca2730b96.pdf/AJMC_ACE0095_05_2018_Biosimilars__Article1.pdf#new_tabhttps://link.springer.com/article/10.1007/s12325-016-0431-5#new_tabhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.638444/full#new_tabhttps://www.sciencedirect.com/science/article/pii/S2667276621000081?via%3Dihub#new_tabhttps://www.fda.gov/drugs/biosimilars/biosimilar-product-information#new_tabhttps://www.fda.gov/drugs/biosimilars/biosimilar-basics-patients#new_tabhttps://www.ajmc.com/view/projected-us-savings-from-biosimilars-2021-2025#new_tabhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355057/#new_tabhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606858/#new_tabhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057195/#new_tabhttps://pubmed.ncbi.nlm.nih.gov/34705051/#new_tabhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042210/#new_tabhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/#new_tabhttps://link.springer.com/article/10.1007/s12325-019-00979-6#new_tabhttps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15101#new_tabhttps://www.dovepress.com/an-update-review-of-biosimilars-of-adalimumab-in-psoriasis--bioequival-peer-reviewed-fulltext-article-DDDT#new_tabhttps://link.springer.com/article/10.1007/s40120-019-0145-0#new_tabhttps://jamanetwork.com/journals/jamaneurology/fullarticle/2800332#new_tabhttps://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1836#new_tabhttps://www.accessdata.fda.gov/drugsatfda_docs/rems/Tysabri_2016-10-14-2016_Full.pdf#new_tabhttps://www.frontiersin.org/articles/10.3389/fphar.2021.789640/full#new_tabhttps://academic.oup.com/ajhp/article/79/14/1158/6563384#new_tabhttps://www.futuremedicine.com/doi/full/10.2217/fon-2021-1584?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org#new_tabhttps://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-use-of-medicines-2023#new_tabhttps://accessiblemeds.org/sites/default/files/2022-09/AAM-2022-Generic-Biosimilar-Medicines-Savings-Report.pdf#new_tabhttps://www.fda.gov/media/166334/download#new_tabhttps://www.fda.gov/media/151058/download#new_tabhttps://www.fda.gov/drugs/biosimilars/curriculum-materials-health-care-degree-programs-biosimilars#new_tabhttps://www.fda.gov/media/154917/download#new_tabhttps://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=63#new_tabhttps://store.ashp.org/Default.aspx?TabID=251&productId=617829176#new_tabhttps://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/humira-biosimilar-landscape-overview.html?cid=GEN-VURL-PHR-CSS-BSM-Humira_Biosimilars-Humira_BSM_Landscape_Overview#new_tabhttps://www.cardinalhealth.com/content/dam/corp/web/documents/Report/cardinal-health-biosimilar-launches.pdf#new_tabhttps://adoptbiosimilars.ashpadvantagemedia.com/rheumatology-biosimilars-landscape/https://adoptbiosimilars.ashpadvantagemedia.com/multiple-sclerosis-biosimilars-landscape//wp-content/uploads/2023/06/Changing-MS-Treatment-Landscape.pdf#new_tabhttps://link.springer.com/article/10.1007/s40265-020-01256-5#new_tabhttps://rmdopen.bmj.com/content/5/1/e000900#new_tabhttps://journals.sagepub.com/doi/10.1177/1756286420987031#new_tab/wp-content/uploads/2023/06/s40744-019-00190-7.pdf#new_tab/wp-content/uploads/2023/06/1-s2.0-S0049017221002171-main.pdf#new_tab/wp-content/uploads/2023/06/Figure-One-Adalimumab-biosimilars-in-US-AJHP-2023.pdfhttps://www.ashp.org/professional-development/ashp-podcasts/ashp-advantage/accelerating-biosimilar-adoption-conversation-with-the-expertshttps://www.ashp.org/professional-development/ashp-podcasts/ashp-advantage/a-new-landscape-biosimilars-in-autoimmune-indications?loginreturnUrl=SSOCheckOnly#new_tabhttps://www.ashp.org/professional-development/ashp-podcasts/ashp-advantage/a-new-landscape-biosimilars-in-multiple-sclerosis#new_tab